A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Clinical trial NCT02588651 · COMPLETED

Trial details

NCT number: NCT02588651
Sponsor: Deepa Jagadeesh
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

T-cell Lymphoma Angioimmunoblastic T-cell Lymphoma Hepato-splenic T-cell Lymphoma Adult T-cell Leukemia/Lymphoma Enteropathy Associated T-cell Lymphoma NK T-cell Lymphoma

Start date: 2016-06-17
Primary completion: 2024-10-14
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.